Actinium Pharmaceuticals, Inc.

AMEX:ATNM

Biotechnology

Healthcare
$1.64 +15.94%

+$0.22 today

Market cap
$51.56M
Beta
0.02
P/E (TTM)
4.4
EPS (TTM)
$0.36
52W Low $0.74High $1.74

Volume 0.18M

Average 0.15M

ATNM Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Actinium Pharmaceuticals, Inc.AMEX: ATNM

Operating Margin · Q2 FY2026 · quarter ended Jun 2026

Operating margin at 78.8%

Operating margin was 78.8% in Q2 FY2026. On a trailing-twelve-month basis it was 27.2%. Over 3 fiscal years it narrowed by 36963.4 pp.

Context

  • Operating margin widened in 1 of the last 2 fiscal years.

What to watch

Whether operating margin reaches the consensus estimate from 2 analysts of 17.7% for the fiscal year ending Dec 2026, up from -40274.4% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
78.8%— QoQ
Last fiscal yearDec 2025
-40274.4%— YoY
LTMJun 2026
27.2%— YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter—+5711.1 pp—
1 year—+40292.2 pp—
3 years-36963.4 pp+38837.1 pp+75800.5 pp
5 years+40197.6 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-40274.4%
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How ATNM compares with its peers on the latest reported figures

  • ATNM's LTM Jun 2026 operating margin of 27.2% is the highest of the 2 companies compared; the peer median is -79.0%.
ATNM Competitors Peer median
Operating Margin for ATNM and competitors
Company Period LTM level YoY 3-year change
ATNMActinium Pharmaceuticals, Inc.LTM Jun 202627.2% —-36963.4 pp
XLOXilio Therapeutics, Inc.LTM Mar 2026-79.0% +535.1 pp—
OKUROnKure Therapeutics, Inc.FY2025— ——
PDSBPDS Biotechnology CorporationFY2025— ——
ANVSAnnovis Bio, Inc.FY2025— ——
Peer median (excluding ATNM) -79.0%+535.1 pp—

Competitors are the stored peer set for ATNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.14M1.03M81K090K
Cost of Revenue524K00811K0
Gross Profit620K1.03M81K(811K)90K
Gross Margin54.2%100.0%100.0%—100.0%
Research & Development17.51M23.14M38.67M30.05M21.12M
Selling, General & Admin8.08M12M13.33M12.08M15.21M
Operating Expenses25.58M35.13M52M41.31M36.34M
Depreciation & Amortization524K699K790K811K821K
EBITDA(24.25M)(32.32M)(48.03M)(37.43M)(33.07M)
EBITDA Margin-2119.8%-3137.7%-59293.8%—-36740.0%
Operating Income(24.96M)(34.1M)(51.92M)(42.12M)(36.25M)
Operating Margin-2182.2%-3311.1%-64098.8%—-40274.4%
Interest Income190K1.09M3.1M3.88M2.36M
Interest Expense00000
Other Income / Expenses190K1.09M3.1M3.88M2.36M
Income Before Tax(24.77M)(33.02M)(48.82M)(38.24M)(33.89M)
Pre-Tax Margin-2165.6%-3205.5%-60269.1%—-37652.2%
Income Tax Expense00000
Net Income(24.77M)(33.02M)(48.82M)(38.24M)(33.89M)
Net Margin-2165.6%-3205.5%-60269.1%—-37652.2%
EPS (Basic)(1.20)(1.37)(1.83)(1.27)(1.09)
EPS (Diluted)(1.20)(1.37)(1.83)(1.27)(1.09)
Weighted Avg Shares20.57M24.14M26.6M30.07M31.2M
Weighted Avg Shares (Diluted)20.57M24.14M26.6M30.07M31.2M

Actinium Pharmaceuticals, Inc.

AMEX:ATNM

Intrinsic Alpha fair value

Locked

Current Price

$1.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.